Sanofi position in TRAX
FIRST TRACKS BIOTHERAPEUTICS · Health Care
Sanofi reported holding 821,917 shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$29.1M, representing 4.62% of its reported portfolio and ranking #8 among its reported holdings. Sanofi has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR
How Sanofi's TRAX position evolved
Sanofi first disclosed a stake in TRAX in Q2 2026 at 821,917 shares (US$16.5M). The position peaked in Q3 2026 at 821,917 shares, worth US$29.1M. Across 2 filings, Sanofi held the position steady without any share-count change. The most recent filing (Q3 2026) shows 821,917 shares valued at US$29.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 821.92K | $16.54M | New |
| Q3 2026 | 821.92K | $29.13M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRAX and 13F data
TRAX (FIRST TRACKS BIOTHERAPEUTICS) is a Health Care company. 156 other funds we track also report a position in TRAX — the largest reported positions include EcoR1 Capital, LLC (US$63.9M), TCG Crossover Management, LLC (US$58.3M), Affinity Asset Advisors, LLC (US$40.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRAX
- EcoR1 Capital, LLC 3.17M sh · $63.87M · Q2 2026
- TCG Crossover Management, LLC 2.90M sh · $58.25M · Q2 2026
- Affinity Asset Advisors, LLC 2.03M sh · $40.88M · Q2 2026
- Trails Edge Capital Partners, LP 1.51M sh · $30.46M · Q2 2026
- Vestal Point Capital, LP 1.01M sh · $20.38M · Q2 2026
- 683 Capital Management, LLC 750.00K sh · $15.09M · Q2 2026
- STEMPOINT CAPITAL LP 622.72K sh · $12.53M · Q2 2026
- Palo Alto Investors LP 603.49K sh · $12.14M · Q2 2026
- Sofinnova Investments, Inc. 565.20K sh · $11.37M · Q2 2026
- Ally Bridge Group (NY) LLC 284.29K sh · $5.72M · Q2 2026
- APIS CAPITAL ADVISORS, LLC 226.00K sh · $4.55M · Q2 2026
- Opaleye Management Inc. 65.00K sh · $1.31M · Q2 2026
FAQ
How long has Sanofi held TRAX?
Sanofi has disclosed TRAX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Sanofi's current position in TRAX?
As of Q3 2026, Sanofi holds 821.92K shares of TRAX (FIRST TRACKS BIOTHERAPEUTICS), valued at $29.13M, representing 4.62% of its reported portfolio and ranking #8.
Has Sanofi been buying or selling TRAX?
In the latest 13F filing (Q3 2026), Sanofi held unchanged its position in TRAX. The position peaked in Q3 2026 at 821.92K shares.
Which other funds hold TRAX?
Other major institutional holders of TRAX include EcoR1 Capital, LLC, TCG Crossover Management, LLC, Affinity Asset Advisors, LLC, among 156 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.